NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Total p65 protein levels remained unchanged after treatment, while phospho‐p65 levels diminished with PTL treatments in both CML cell lines and in a primitive population from a CML patient, indicating an inhibition of the NF‐κB canonical pathway (Figure 5B).